Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:LEGNNASDAQ:LNTHNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$50.73+2.2%$41.36$17.86▼$58.40$4.04B-0.12984,346 shs1.83 million shsLEGNLegend Biotech$29.32+1.3%$31.68$27.34▼$60.87$5.39B0.21.29 million shs1.44 million shsLNTHLantheus$77.13+2.1%$91.65$73.11▼$126.89$5.34B0.23992,563 shs1.08 million shsRVMDRevolution Medicines$40.65+3.2%$37.62$29.17▼$62.40$7.34B1.111.52 million shs2.67 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.57%+9.43%+13.06%+13.92%+169.55%LEGNLegend Biotech+1.98%+1.42%-11.61%-13.71%-26.72%LNTHLantheus+2.15%+4.43%-29.07%-21.43%-5.74%RVMDRevolution Medicines+1.68%+2.21%-0.17%+7.09%+6.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.9266 of 5 stars3.53.00.04.72.11.70.0LEGNLegend Biotech3.1986 of 5 stars4.52.00.00.02.91.70.6LNTHLantheus4.4611 of 5 stars3.51.00.04.23.62.51.9RVMDRevolution Medicines4.2786 of 5 stars4.50.00.04.73.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5062.63% UpsideLEGNLegend Biotech 2.91Moderate Buy$76.20159.89% UpsideLNTHLantheus 3.00Buy$132.6772.00% UpsideRVMDRevolution Medicines 3.00Buy$67.0865.03% UpsideCurrent Analyst Ratings BreakdownLatest AKRO, RVMD, LNTH, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/14/2025LEGNLegend BiotechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $71.005/14/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ALEGNLegend Biotech$728.30M7.40N/AN/A$6.88 per share4.26LNTHLantheus$1.54B3.47$6.44 per share11.98$11.91 per share6.48RVMDRevolution Medicines$742K10,204.57N/AN/A$11.09 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)LEGNLegend Biotech-$518.25M-$0.59N/AN/AN/A-66.92%-29.69%-19.45%8/8/2025 (Estimated)LNTHLantheus$326.66M$3.5212.8312.22N/A28.57%44.29%23.52%7/30/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)Latest AKRO, RVMD, LNTH, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25LEGNLegend Biotech0.274.984.90LNTHLantheusN/A1.651.56RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ALEGNLegend Biotech70.89%LNTHLantheus99.06%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%LEGNLegend Biotech0.02%LNTHLantheus1.50%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionableLEGNLegend Biotech1,070183.76 million182.60 millionOptionableLNTHLantheus70069.19 million68.48 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableAKRO, RVMD, LNTH, and LEGN HeadlinesRecent News About These CompaniesUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)June 1 at 4:08 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from AnalystsJune 1 at 3:48 AM | marketbeat.com22,725 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Jefferies Financial Group Inc.May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Has $2.09 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 30, 2025 | marketbeat.comHead to Head Review: Fate Therapeutics (NASDAQ:FATE) versus Revolution Medicines (NASDAQ:RVMD)May 30, 2025 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Shares Up 3.9% - Should You Buy?May 29, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's WhyMay 28, 2025 | marketbeat.comPolar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 28, 2025 | marketbeat.comRevolution Medicines’ SWOT analysis: stock shows promise amid clinical progressMay 27, 2025 | investing.comNuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by ProShare Advisors LLCMay 23, 2025 | marketbeat.comBank of America Corp DE Has $17.54 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 23, 2025 | marketbeat.comWoodline Partners LP Has $169.96 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 503,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 21, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.May 21, 2025 | marketbeat.comRevolution Medicines Inc.May 20, 2025 | wsj.comTang Capital Management LLC Invests $4.37 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comTema Etfs LLC Invests $1.99 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comMan Group plc Buys 65,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comDeutsche Bank AG Has $7.76 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreAKRO, RVMD, LNTH, and LEGN Company DescriptionsAkero Therapeutics NASDAQ:AKRO$50.73 +1.08 (+2.18%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$51.08 +0.35 (+0.69%) As of 06/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Legend Biotech NASDAQ:LEGN$29.32 +0.37 (+1.28%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$29.48 +0.16 (+0.53%) As of 06/2/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Lantheus NASDAQ:LNTH$77.13 +1.57 (+2.08%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$77.13 0.00 (0.00%) As of 06/2/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Revolution Medicines NASDAQ:RVMD$40.65 +1.25 (+3.17%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$41.20 +0.55 (+1.34%) As of 06/2/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
